mAbxience Research S.L. clinical trials
Acquired by Fresenius Kabi, Aug 1, 2022 · source ↗
The registry lists 15 studies whose lead sponsor is mAbxience Research S.L.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 8, 2026.
Before and after it joined Fresenius Kabi
- First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- 11
- First submitted after mAbxience Research S.L. became part of Fresenius Kabi
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- mAbxience Research S.L.15 studies
Something wrong with this grouping? Tell us on the Fresenius Kabi page.
Studies
Recruiting first, then most recently updated. Showing 15 of 15. All Fresenius Kabi studies →
- Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] MelanomaRecruitingNCT07221734Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi
- A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisCompletedNCT06596772Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi
- A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)Active, not recruitingNCT06687369Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi
- A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune DisordersCompletedNCT06392074Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted after mAbxience Research S.L. became part of Fresenius Kabi
- A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.CompletedNCT05121246Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.CompletedNCT05338086Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced XgevaCompletedNCT05299073Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.CompletedNCT04408989Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT04238663Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSVCompletedNCT04540627Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03296163Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male VolunteersCompletedNCT04238650Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male VolunteersCompletedNCT03293654Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's LymphomaCompletedNCT02268045Phase 3
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi
- Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC PatientsCompletedNCT02069704Phase 1
Sponsor listed in the registry: mAbxience Research S.L. · First submitted before mAbxience Research S.L. became part of Fresenius Kabi